The 1 analysts offering 12-month price forecasts for Arch Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +7,400.00% increase from the last price of 0.04.
The current consensus among 1 polled investment analysts is to Buy stock in Arch Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.01
Reporting Date Nov 30
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.